[HTML][HTML] Enhancing mesenchymal stem cell survival and homing capability to improve cell engraftment efficacy for liver diseases
S Yu, S Yu, H Liu, N Liao, X Liu - Stem Cell Research & Therapy, 2023 - Springer
Although mesenchymal stem cell (MSC) transplantation provides an alternative strategy for
end-stage liver disease (ESLD), further widespread application of MSC therapy is limited …
end-stage liver disease (ESLD), further widespread application of MSC therapy is limited …
Multiple dimensions of using mesenchymal stem cells for treating liver diseases: From bench to beside
L Chen, N Zhang, Y Huang, Q Zhang, Y Fang… - Stem Cell Reviews and …, 2023 - Springer
Liver diseases impose a huge burden worldwide. Although hepatocyte transplantation has
long been considered as a potential strategy for treating liver diseases, its clinical …
long been considered as a potential strategy for treating liver diseases, its clinical …
Role of the immune system in liver transplantation and its implications for therapeutic interventions
G Chen, X Hu, Y Huang, X Xiang, S Pan, R Chen… - MedComm, 2023 - Wiley Online Library
Liver transplantation (LT) stands as the gold standard for treating end‐stage liver disease
and hepatocellular carcinoma, yet postoperative complications continue to impact survival …
and hepatocellular carcinoma, yet postoperative complications continue to impact survival …
Human amniotic epithelial cell transplantation is safe and well tolerated in patients with compensated cirrhosis: a first-in-human trial
R Lim, A Hodge, S Warner, GT Moore… - Stem cells …, 2024 - academic.oup.com
Placenta-derived human amniotic epithelial cells (hAEC) exhibit anti-inflammatory and anti-
fibrotic effects in cirrhosis models. We conducted a first-in-human phase I clinical trial to …
fibrotic effects in cirrhosis models. We conducted a first-in-human phase I clinical trial to …